Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, China.
Diagn Pathol. 2012 Jul 18;7:84. doi: 10.1186/1746-1596-7-84.
To investigate the expression of aurora kinase A and B in patients with chondrosarcoma and consider it as a prognostic marker and molecular target of therapy.
To evaluate the relationship of the aurora kinase A and B and the clinical pathological parameters and prognosis of chondrosarcoma. 72 case chondrosarcoma and 42 case chondroma were performed immunohistochemistry on the tissue microarray paraffin sections. The survival time of patients was followed-up.
The expression of aurora kinase A and B in chondrosarcoma was significantly higher than that in chondroma (p<0.01). There were differences about the expression of aurora kinase A and B in chondrosarcoma between the recurrence group and the non-recurrence group, metastatic group and non-metastatic group (p<0.05), but not age and gender (p>0.05). The expression of aurora kinase A and B were significantly lower in group low grade conventional chondrosarcoma than that in groups medium and high grade conventional chondrosarcoma (p<0.01). The expression of aurora kinase A and B in chondrosarcoma showed a positive correlation (p<0.01). According to the Kaplan Meier analysis and multivariate Cox regression analysis, the survival rate was significantly different between the patients with positive aurora kinase A and the patients with negative expression (p<0.05) and aurora kinase A expression was an independent risk marker of survival (HR=11.263, 95%CI: 2.317-54.748, P=0.003).
Both the aurora kinase A and B might involve in the oncogenic, invasive and metastatic process of chondrosarcoma; however, the mechanism is still unclear. The aurora kinase A and B could be used as a new prognostic marker and molecular therapeutic target for chondrosarcoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9101494267377096.
研究极光激酶 A 和 B 在软骨肉瘤患者中的表达情况,并将其作为一种预后标志物和治疗的分子靶点。
评估极光激酶 A 和 B 与软骨肉瘤临床病理参数和预后的关系。对组织微阵列石蜡切片进行免疫组织化学检测,共检测 72 例软骨肉瘤和 42 例软骨瘤。对患者的生存时间进行随访。
软骨肉瘤中极光激酶 A 和 B 的表达明显高于软骨瘤(p<0.01)。在复发组和未复发组、转移组和未转移组之间,极光激酶 A 和 B 的表达存在差异(p<0.05),但与年龄和性别无关(p>0.05)。低级别常规型软骨肉瘤组中极光激酶 A 和 B 的表达明显低于中级别和高级别常规型软骨肉瘤组(p<0.01)。软骨肉瘤中极光激酶 A 和 B 的表达呈正相关(p<0.01)。根据 Kaplan-Meier 分析和多因素 Cox 回归分析,极光激酶 A 阳性表达患者的生存率明显低于阴性表达患者(p<0.05),且极光激酶 A 表达是生存的独立危险因素(HR=11.263,95%CI:2.317-54.748,P=0.003)。
极光激酶 A 和 B 可能都参与了软骨肉瘤的致癌、浸润和转移过程,但机制尚不清楚。极光激酶 A 和 B 可作为软骨肉瘤的一种新的预后标志物和分子治疗靶点。